Nanoparticle Delivery of Anti-Tuberculosis Chemotherapy as a Potential Mediator Against Drug-Resistant Tuberculosis

Drug-resistant tuberculosis is quickly emerging as one of the largest threats to the global health community. Current chemotherapy for tuberculosis dates back to the 1950s and is arduous, lengthy, and remains extremely difficult to complete in many of the highest burdened areas. This causes inadequate or incomplete treatment, resulting in genetic selection of drug-resistant strains. With a dearth of novel anti-TB drug candidates in the development pipeline, nanoparticle technology allows us to take current chemotherapies and deliver them more efficaciously, reducing the frequency and duration of treatment and increasing bioavailability. This approach can improve patient adherence, reduce pill burden, and shorten time to completion, all which are at the heart of drug resistance. This review examines the multiple advantages of nanoparticle drug delivery of tuberculosis chemotherapy and summarizes the challenges in implementation.

[1]  俊郎 黒木,et al.  Centers for Disease Control and Prevention (CDC) ホームページの活用法 , 2002 .

[2]  J. Sacchettini,et al.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. , 1998, Science.

[3]  A. Florence.  Issues in Oral Nanoparticle Drug Carrier Uptake and Targeting , 2004, Journal of drug targeting.

[4]  R. Pandey,et al.  Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, Journal of Antimicrobial Chemotherapy.

[5]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[6]  Ying Zhang,et al.  Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. , 2003, The Journal of antimicrobial chemotherapy.

[7]  P. Bummer,et al.  Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles. , 2004, Critical reviews in therapeutic drug carrier systems.

[8]  S. Simeoni,et al.  Effect of nanoparticle encapsulation on the photostability of the sunscreen agent, 2-ethylhexyl-p-methoxycinnamate. , 2002, International journal of pharmaceutics.

[9]  R. Pandey,et al.  Nanomedicine and experimental tuberculosis: facts, flaws, and future. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[10]  R. Pandey,et al.  Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. , 2004, The Journal of antimicrobial chemotherapy.

[11]  L. Heifets,et al.  Nanoparticles as Antituberculosis Drugs Carriers: Effect on Activity Against Mycobacterium tuberculosis in Human Monocyte-Derived Macrophages , 2000 .

[12]  G. Besra,et al.  Biogenesis of the mycobacterial cell wall and the site of action of ethambutol , 1995, Antimicrobial agents and chemotherapy.

[13]  P. Schultz,et al.  Studies on the Mechanism of Action of Isoniazid and Ethionamide in the Chemotherapy of Tuberculosis , 1995 .

[14]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[15]  R. Pandey,et al.  Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. , 2003, Tuberculosis.

[16]  Ying Zhang,et al.  Mechanisms of drug resistance in Mycobacterium tuberculosis. , 2009, Frontiers in bioscience : a journal and virtual library.

[17]  T. Holtz,et al.  Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study , 2005, The Lancet.

[18]  F. Bonini,et al.  Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity , 1998 .

[19]  J. Andrews,et al.  Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. , 2008, The Journal of infectious diseases.

[20]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[21]  K. Kisich,et al.  The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. , 2005, American journal of respiratory and critical care medicine.

[22]  박태관.  Nanoparticles for Drug Delivery System , 2007 .

[23]  S. Bihari,et al.  A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  B. U. Bowman,et al.  Peroxidase-mediated oxidation of isoniazid , 1985, Antimicrobial Agents and Chemotherapy.

[25]  Anjali Sharma,et al.  Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. , 2004, International journal of antimicrobial agents.

[26]  N Hussain,et al.  Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. , 2001, Advanced drug delivery reviews.

[27]  S. Croft,et al.  Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs , 2003, Parasitology Research.

[28]  R Zajtchuk,et al.  New technologies in medicine: biotechnology and nanotechnology. , 1999, Disease-a-month : DM.

[29]  Z. F. Zainuddin,et al.  Does Mycobacterium tuberculosis have plasmids? , 1990, Tubercle.

[30]  S. Lawn,et al.  HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response , 2009, The Lancet.

[31]  S. Cole,et al.  Mechanisms of drug resistance in Mycobacterium tuberculosis. , 1994, Immunobiology.

[32]  P. Brennan.  Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. , 2003, Tuberculosis.

[33]  A. Hickey,et al.  Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation , 2009, Antimicrobial Agents and Chemotherapy.

[34]  M. Daffé,et al.  The envelope layers of mycobacteria with reference to their pathogenicity. , 1998, Advances in microbial physiology.

[35]  D. Quenelle,et al.  Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis-Infected Macrophages , 1998, Antimicrobial Agents and Chemotherapy.

[36]  H. Nikaido,et al.  Mycobacterial cell wall: structure and role in natural resistance to antibiotics. , 1994, FEMS microbiology letters.

[37]  P. Couvreur,et al.  Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. , 2000, International journal of antimicrobial agents.